Jazz PharmaceuticalsJAZZ
Recorded

Jazz Pharmaceuticals Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration28 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Phoebe TanAnalyst

Perfect. My name is Phoebe Tan. I work with Akash Tewari, and he's currently at a lunch, and he'll be running over shortly. I have the pleasure of introducing Jazz. I'll pass it over for intro remarks.

John BluthHead of Investor Relations

Yeah, great. Thanks. Thanks very much, Phoebe, for having us here.

John BluthHead of Investor Relations

Renee and I will be making some forward-looking statements today, so please do refer to the risk factors in our securities filings. If we do refer to any guidance, it'll be the guidance as of our last earnings update, and that may include reference to non-GAAP financials, so please do look at the reconciliations that we provide there. Now I'd like to hand it over to our CEO, Renée Galá, who can tell you more about Jazz.

Renee GalaPresident and CEO

Great. Thank you, and thanks for all of you for joining. Hopefully, Akash will be here shortly. I am really excited to be here with all of you today. It's an incredible time to be at Jazz right now as we continue building a more innovative and diversified company for the future. I would say that starts looking at our execution across the year. We've had excellent execution, which we announced as recent in our most recent third quarter earnings. We had record revenues of $1.24 billion, 10% year-over-year growth, giving us the confidence once again to raise our full-year guidance to $4.775 billion-$4.85 billion for 2026. As you look across commercial, our pipeline, and business development, we're seeing positive momentum across each of those.

Renee GalaPresident and CEO

Really driving our commercial performance and giving us the confidence to raise the guidance came across our sleep, epilepsy, and oncology portfolios, all performing well. In terms of our pipeline, we had our most recent approval for Ziihera in first-line metastatic GEA, HER2-positive metastatic GEA. This is a very important approval for us. The launch is off to a great start, and all of that momentum is backed by really strong clinical data behind the GEA study, which showed 27 months of median overall survival, which is unprecedented in this patient population. We are investing significantly behind this molecule with an extensive development program and giving us the confidence to provide peak sales guidance of $3 billion-$5 billion over the course of the life of this program, backed by the various development programs that we're expanding into.

Renee GalaPresident and CEO

Just to close from a value-driving perspective, we're investing behind commercial, investing behind our pipeline, but also investing in business development. We closed the Actio transaction in the third quarter of this year. We're excited to share data from that program later this quarter at a major medical conference that will be upcoming. We're excited to be able to demonstrate what we are bringing into the company to provide additional growth drivers, being very disciplined about our approach to business development and aligned to our rare disease strategy that we outlined earlier this year. Importantly, we're well capitalized with a strong balance sheet and continued strong cash flows to be able to invest in each of these drivers of our business and look forward to sharing more throughout the Q&A.

Phoebe TanAnalyst

Perfect. Just building off of that, with Zani, Modeyso, and Actio together, it seems like you're adding growth opportunities to franchises that you already have. How much of an advantage does the existing infrastructure provide for earnings and synergy?

Renee GalaPresident and CEO

Yeah, so certainly, as we outlined earlier this year, we had every intention of sharpening our focus in rare disease, and in particular, when it comes to business development, building on our rare epilepsy, rare sleep, and rare oncology portfolios, and potentially, how are you? And potentially expanding beyond that into other areas of rare disease. Certainly, we can get more operating leverage out of our existing franchises when we're building greater breadth on the expertise and experience that we already have. The capabilities that we have, for example, for Actio, will bode quite nicely as we continue to rapidly push that program forward. So we'll continue investing in business development and look at opportunities to grow the business in that way, and then continue to invest in our existing organic business as well.

Akash TewariAnalyst

Okay, there we go. Nice bridge. Give me a little time to catch my breath. I really do appreciate, Renee, you coming over, though. It's great to have you. I can tell you, personally, Jazz is one of the most exciting names in our opinion going into next year. I think it's a big credit to really what you're delivering and building on. I want to start with that, because I feel like with investor discussions, when it goes to the pipeline, you have the post-Enhertu trial, there's the Zani launch, and that's pretty much it. When I look at the catalysts you have, particularly in the first half of the year, there's a lot of dark horses that are actually super accretive because you already have an existing sales force. I think about Actio and how quickly that can get on the market.

Akash TewariAnalyst

I think about a potential CRC Zani pan-tumor indication. I think about Modeyso working in kind of frontline glioblastoma. I can't help but think all of those would be highly accretive to your current business. Talk to me about First of all, do you think the street is accounting for that opportunity right now? Could you size up some of the revenue opportunities, if you can, with some of those, let's say, under-followed opportunities?

Renee GalaPresident and CEO

Yeah. I'm not sure I am best positioned to say what investors are getting or not. I can say what we're focused on and what we're focused on delivering, myself as CEO, other members of the team I see in the audience. We are highly focused on building a durable, diversified business, and one that is not solely dependent on business development going forward. We have executed some incredible deals that we are all really proud of. In particular, in the last question, we talked about the ability to invest further in areas where you already have capabilities and expertise. With Modeyso, which came to us through the Chimerix acquisition, that is an asset that we've said we think has $500 million peak potential in the U.S.

Renee GalaPresident and CEO

That asset is performing well, and financially, from a discipline perspective, that acquisition was less than $900 million. We have an incredible asset that came with it, great expertise in neuro-oncology, but also real cash benefits that come in the form of $200 million in deferred tax assets. We had a priority review voucher that came that we sold for $200 million, $100 million of that came back to Jazz. When you just step back and look at the discipline and value that can be created through that transaction, those are the type of deals that I think bode very well for our business and for our shareholders. When it comes to Actio, this is another opportunity to have a meaningful impact for patients. There's nothing approved in KCNT1 epilepsy, and this is a very severe, debilitating form of epilepsy.

Renee GalaPresident and CEO

There's some anecdotes already available in the public about patients that have been treated through EAP, but we're excited to share data later this quarter, as I mentioned, which I think will give investors a really good view on the type of efficacy we can expect to see with this molecule. When we look broadly about the opportunity to bring these assets into our business while we are simultaneously expanding our R&D capabilities and now have Jazz-discovered assets that have come from Jazz research lab into the clinic, that's created more durability into our business, where we can both build on the business development side, but also with greater capacity in R&D, continue to push forward our own R&D programs as well.

Akash TewariAnalyst

Understood. Just to highlight a bit on that, because again, where I feel like people miss is, I mean, these couldn't just be, will matter at the end of the decade. These could start impacting the P&L maybe in 2027 and 2028. Let's start a bit with, we have, I think, ACTION, the frontline Modeyso glioblastoma study reading out. My guess is you probably already have some frontline use given it's such a debilitating disorder. But, can you remind us when does that study come out? What's your team's internal confidence that you'll see a positive signal given the data you've already generated? Then how quickly does that get you to Because you're well on the way to that $500 million run rate for Modeyso already. How quickly does that result actually translate to the bottom line in terms of commercial performance?

Renee GalaPresident and CEO

Yeah. So, I think you're right. We probably already have some first-line use, but the ACTION study serves as a confirmatory study and a frontline study for Modeyso. Of course, we do not promote off-label. We only promote for the medicine's approved use, but we do expect that to read out in the first half of next year. We are still gaining insight into the duration of treatment with respect to Modeyso, and so I think there are a couple of different angles in terms of continuing to see growth with that product. One is first-line approval and being able to have that in the label, which would have the use earlier. Two would be getting a better feel for duration of therapy. Then, I would say three, continued penetration into the The medicine is well-known, but continued penetration both through institutions and into the community.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day